Innoviva

Update in progress

INVA (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Innoviva, Inc. is a biopharmaceutical company with a global royalties portfolio. It markets RELVAR/BREO ELLIPTA (vilanterol and fluticasone furoate) and ANORO ELLIPTA (umeclidinium and vilanterol) for COPD and asthma. It also sells GIAPREZA, XACDURO, XERAVA, ZEVTERA, and NUZOLVENCE, and develops bacteriophages. Partnerships include Sarissa Capital and Glaxo Group Limited. Formerly Theravance; renamed in 2016. Founded 1996; based in Burlingame, California.

Company score

Sentiment: 0.51; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.69; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.14; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.24; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.37; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive